Papers reviewed not cited S-Z

  1. Salinas GD, Williamson JC, Kalhan R, Thomashow B, Scheckermann JL, Walsh J, Abdolrasulnia M, Foster JA. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. International Journal of COPD 2011:6 171–179
  2. Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Randomized Controlled Trials. J Gen Intern Med 2003; 18: 213-221
  3. Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006;31(2-3):219-30
  4. Sampablo I, Carone M, Antoniu SA. Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10): 948-55.
  5. Sanchez-Salcedo P, Divo M, Casanova C, Pinto-Plata V, de-Torres JP, Cote C, Cabrera C, Zagaceta J, Rodriguez-Roisin R, Zulueta JJ, Marin JM, Celli B. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. Eur Respir J. 2014 Aug;44(2):324-31.
  6. Sandland CJ, Morgan MD, Singh SJ. Patterns of domestic activity and ambulatory oxygen usage in COPD. Chest. 2008 Oct;134(4):753-60
  7. Santiworakul A, Jarungjitaree S, Jalayondeja W, Chantarothorn S, Supaibulpipat S. Effect of lower extremity exercise on muscle strength and physical capacity in COPD patients. J Med Assoc Thai. 2009 Apr;92(4):556-63
  8. Sasaki T, Nakayama K, Yasuda H, Yoshida M, Asamura T, Ohrui T, Arai H, Araya J, Kuwano K, Yamaya M. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc. 2009 Aug;57(8):1453-7.
  9. Sava F, Laviolette L, Bernard S, Breton M-J, Bourbeau J, Maltais F. The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulmonary Medicine 2010, 10:55 doi:10.1186/1471-2466-10-55
  10. Scala R, Naldi M, Maccari U. Early fiberoptic bronchoscopy during non-invasive ventilation in patients with decompensated chronic obstructive pulmonary disease due to community-acquired-pneumonia. Critical Care 2010, 14:R80
  11. Schachter EN. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc). 2013 Jul;49(7):437-46.
  12. Schembri S, Morant S, Winter JH, MacDonald TM. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009 Jul;64(7):567-72
  13. Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal Vaccination for Patients With COPD: Current Practice and Future Directions. Chest 2008;133:767–774
  14. Scher DL, Arsura EL. Multifocal atrial tachycardia: mechanisms, clinical correlates, and treatment. Am Heart J 1989 Sep;118(3):574-80
  15. Schermer TRJ & Quanjer PH. COPD screening in primary care: who is sick? Primary Care Respiratory Journal 2007;16(1):49-53
  16. Schermer T, Leenders J, Veen H, van den Bosch W, Wissink A, Smeele I, Chavannes N. Pulse oximetry in family practice: indications and clinical observations in patients with COPD. Fam Pract. 2009 Dec;26(6):524-31
  17. Schneider A, Ay M, Faderl B, Linde K, Wagenpfeil S. Diagnostic accuracy of clinical symptoms in obstructive airway diseases varied within different health care sectors. J Clin Epidemiol. 2012 Aug;65(8):846-54. Epub 2012 May 27.
  18. Schuetz P, Christ-Crain M, Schild U, Süess E, Facompre M, Baty F, Nusbaumer C, Brutsche M, Müller B. Effect of a 14-day course of systemic corticosteroids on the hypothalamicpituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary Medicine 2008, 8:1 doi:10.1186/1471-2466-8-1
  19. Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ). COPD 2005;2(1):81-9
  20. Scott I and Del Mar C. Editorial: A dog walking on its hind legs: Implications of the Care Track study. MJA 197(2) 16 July 2012: 67-68.
  21. Scott I and Glaszlou P. Improving effectiveness of clinical medicine translation of science into practice MJA 197(7) 1 October 2012: 374-378
  22. Sellares J, Lopez-Giraldo A, Lucena C, Cilloniz C, Amaro R, Polverino E, Ferrer M, Menendez R, Mensa J, Torres A. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia. Am J Respir Crit Care Med Vol 187, Iss. 11, pp 1241–1248, Jun 1, 2013
  23. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006;61;1043-104
  24. Sharafkhaneh A, Mattewal AS, Abraham VM, Dronavalli G, Hanania NA. Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis. 2010 Oct 5;5:357-66. doi: 10.2147/COPD.S4215
  25. Sharma G, Kuo YF, Freeman JL, Zhang DD, Goodwin JS. Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med. 2010 Oct 11;170(18):1664-70
  26. Shea SD, Taylor NF, Paratz J. Peripheral muscle strength training in COPD: a systematic review. Chest 2004;126(3): 903-914
  27. Sillen MJ, Franssen FM, Delbressine JM, Vaes AW, Wouters EF, Spruit MA. Efficacy of lower-limb muscle training modalities in severely dyspnoeic individuals with COPD and quadriceps muscle weakness: results from the DICES trial. Thorax. 2014 Jun;69(6):525-31.
  28. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. JAMA 2003;290(17):2301-2312
  29. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. Cite this as: BMJ 2011;342:d3215doi:10.1136/bmj.d3215
  30. Slatore CG, Cecere LM, Reinke LF, Ganzini L, Udris EM, Moss BR, Bryson CL, Curtis JR, Au DH. Patient-clinician communication: associations with important health outcomes among veterans with COPD. Chest. 2010 Sep;138(3):628-34.
  31. Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Medical Research Methodology 2011, 11:15
  32. Smith TA, Davidson PM, Lam LT, Jenkins CR, Ingham JM. The use of non‐invasive ventilation for the relief of dyspnoea in exacerbations of chronic obstructive pulmonary disease: a systematic review. Respirology.2012;17(2):300‐307
  33. Smith-Sivertsen T and Rortveit G. Should general practitioners screen smokers for COPD. Scand J Prim Health Care 2004;22:196-201
  34. Snyder ML, Goss CH, Neradilek B, Polissar NL, Mosenifar Z, Wise RA, Fishman AP, Benditt JO; National Emphysema Treatment Trial Research Group. Changes in arterial oxygenation and self-reported oxygen use after lung volume reduction surgery. Am J Respir Crit Care Med. 2008 Aug 15;178(4):339-45
  35. Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Clin Ther. 2008 Aug;30(8):1416-25
  36. Soler-Cataluna JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Aguero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, Gonzalez MC, Miravitlles M, Monso E, Montemayor  T, Morera J, Ortega F, Peces-Barba G, Puente L, Miguel Rodriguez J, Sala E, Sauleda J, Soriano JB, Viejor JL. Consensus Document on the Overlap Phenotype COPD–Asthma in COPD. Arch Bronconeumol. 2012;48(9):331–337
  37. Sorensen L et al. Medication reviews in the community: results of a randomised controlled effectiveness trial. British Journal of Clinical Pharmacology 2004;58(6):648-664
  38. Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2008 Mar;63(3):194-200
  39. Stav D, Raz M, Shpirer I. Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. BMC Pulm Med. 2009 May 30;9:26
  40. Stefan MS, Rothberg MB, Shieh MS, Pekow PS, Lindenauer PK. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest. 2013 Jan;143(1):82-90
  41. Steurer-Stey C, Bachmann LM, Steurer J, Tramer MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126(5): 1645-1655
  42. Stiell IG, Clement CM, Aaron SD, Rowe BH, Perry JJ, Brison RJ, et al. Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. CMAJ. 2014;186(6):E193-204.
  43. Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/ usual therapy: results of a meta-analysis. Respiratory Research 2006;7:147
  44. Strange et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulmonary Medicine 2007, 7:10
  45. Strong M, South G, Carlisle R. The UK Quality and Outcomes Framework pay-for-performance scheme and spirometry: rewarding quality or just quantity? A cross-sectional study in Rotherham, UK. BMC Health Serv Res. 2009 Jun 28;9:108
  46. Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy. Respir Res. 2015 Feb 15;16:25.
  47. Sutherland E Rand. Inhaled steroids and outcomes in COPD: Progressing beyond FEV1. Chest 2007;131(3):648-649
  48. Ta M, Johnson G. Management of COPD in Australia after the publication of national guidelines. Internal Medicine Journal 2009 doi: 10.1111/j.1445-5994.2009.02133
  49. Tanabe N, Muro S, Hirai T, Oguma T, Terada T, Marumo S, Kinose D, Ogawa E, Hoshino Y, Mishima M. Impact of Exacerbations on Emphysema Progression in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2011;183:1653-1659
  50. Thomas MJ, Simpson J, Riley R, Grant E. The impact of home-based physiotherapy interventions on breathlessness during activities of daily living in severe COPD: a systematic review. Physiotherapy. 2010 Jun;96(2):108-19
  51. Thornton Snider J, Luna Y, Wong KS, Zhang J, Chen SS, Gless PJ, Goldman DP. Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin. 2012 Dec;28(12):1959-67. doi: 10.1185/03007995.2012.743459. Epub 2012 Nov 27.
  52. Tierney WM et al. Can computer-generated evidence-based care suggestions enhance evidence-based management of asthma and chronic obstructive pulmonary disease? A randomized, controlled trial. Health Serv Res. 2005 Apr;40(2): 477-97
  53. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006;73(3):296-305
  54. To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population. Respir Med. 2012 Dec;106(12):1715-21. doi: 10.1016/j.rmed.2012.09.002. Epub 2012 Oct 5.
  55. Toljamo T, Kaukonen M, Nieminen P, Kinnula VL. Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care. 2010 Mar;28(1):41-6
  56. Trappenburg JC, van Deventer AC, Troosters T, Verheij TJ, Schrijvers AJ, Lammers JW, Monninkhof EM. The impact of using different symptom-based exacerbation algorithms in patients with COPD. Eur Respir J. 2011 May;37(5):1260-8
  57. Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer M, Gosselink R. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 May 15;181(10):1072-7
  58. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J. 2011 Sep;20(3):257-68
  59. University of York Cochrane Centre for Reviews, Dissemination. Inhaler devices for the management of asthma and COPD. Effective Health Care 2003;8(1):1-12
  60. Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3):289-304
  61. Uronis H, McCrory DC, Samsa G, Currow D, Abernethy A. Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: Reviews 2011 Issue 6 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD006429.pub2
  62. Usmani ZA, Carson KV, Cheng JN, Esterman AJ, Smith BJ. Pharmacological interventions for the treatment of anxiety disorders in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008483. DOI: 10.1002/14651858.CD008483.pub2
  63. Vaes AW, Annegarn J, Meijer K, Cuijpers MW, Franssen FM, Wiechert J, Wouters EF, Spruit MA. The effects of a “new” walking aid on exercise performance in patients with COPD: a randomized crossover trial. Chest. 2012 May;141(5):1224-32
  64. van den Bemt L, Schermer TR, Smeele IJ, Boonman-de Winter LJ, van Boxem T, Denis J, Grootens-Stekelenburg JG, Grol RP, van Weel C. An expert-supported monitoring system for patients with chronic obstructive pulmonary disease in general practice: results of a cluster randomised controlled trial. Med J Aust. 2009 Sep 7;191(5):249-54
  65. van Dijk WD, van den Bemt L, van Weel C. Megatrials for bronchodilators in chronic obstructive pulmonary disease (COPD) treatment: time to reflect. J Am Board Fam Med. 2013 Mar-Apr;26(2):221-4. doi: 10.3122/jabfm.2013.02.110342.
  66. van Helvoort HA, de Boer RC, van de Broek L, Dekhuijzen R, Heijdra YF. Exercises commonly used in rehabilitation of patients with chronic obstructive pulmonary disease: cardiopulmonary responses and effect over time. Arch Phys Med Rehabil. 2011 Jan;92(1):111-7
  67. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010 Dec;65(12):1086-91
  68. van Wetering CR, Hoogendoorn M, Mol SJM, Rutten-van Mo¨lken MPMH, Schols AM. Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax 2010;65:7–13
  69. Vanfleteren LE, Franssen FM, Wesseling G, Wouters EF. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir Med. 2012 Jun;106(6):871-4
  70. Varma-Basil M, Dwivedi SK, Kumar K, Pathak R, Rastogi R, Thukral SS, Shariff M, Vijayan VK, Chhabra SK, Chaudhary R. Role of Mycoplasma pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease. J Med Microbiol. 2009 Mar;58(Pt 3):322-6
  71. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTAN study group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005;60(4):301-4
  72. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011 Sep 29;365(13):1184-92
  73. Vestbo J, Soriano JB, Anderson JA, Calverley P, Pauwels R, Jones P, TRISTAN Study Group. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. 2004
  74. Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, MacNee W, Miller B, Rennard SI, Silverman EK, Yates JC, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Am J Respir Crit Care Med. 2014 May 1;189(9):1022-30.
  75. Vincent E, Sewell L, Wagg K, Deacon S, Williams J, Singh S. Measuring a change in self-efficacy following pulmonary rehabilitation: an evaluation of the PRAISE tool. Chest. 2011 Dec;140(6):1534-9
  76. Vitry AI and Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. MJA 2008; 189: 360–365
  77. Vivodtzev I, Debigaré R, Gagnon P, Mainguy V, Saey D, Dubé A, Paré MÈ, Bélanger M, Maltais F. Functional and muscular effects of neuromuscular electrical stimulation in patients with severe COPD: a randomized clinical trial. Chest. 2012 Mar;141(3):716-25
  78. Vonbank K, Strasser B, Mondrzyk J, Marzluf BA, Richter B, Losch S, Nell H, Petkov V, Haber P. Strength training increases maximum working capacity in patients with COPD–randomized clinical trial comparing three training modalities. Respir Med. 2012 Apr;106(4):557-63
  79. Wakabayashi R, Motegi T, Yamada K, Ishii T, Gemma A, Kida K. Presence of in-home caregiver and health outcomes of older adults with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2011 Jan;59(1):44-9. doi: 10.1111/j.1532-5415.2010.03222.x
  80. Walker PP, Burnett A, Flavahan PW, Calverley PM. Lower limb activity and its determinants in COPD. Thorax. 2008 Aug;63(8):683-9
  81. Walters JA, Hansen EC, Johns DP, Blizzard EL, Walters EH, Wood-Baker R. A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD. Thorax. 2008 May;63(5):408-14. Epub 2007 Nov 16
  82. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011 Aug;140(2):331-42
  83. Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, Smith C, Man WD, Tal-Singer R, Edwards LD, Calverley PM, Magnussen H, Polkey MI, Wouters EF. Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study.  Respiratory Medicine 2012;106:522-530
  84. Watz H, Waschki B, Kirsten A, Müller KC, Kretschmar G, Meyer T, Holz O, Magnussen H. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009 Oct;136(4):1039-46
  85. Wauters E, Janssens W, Lambrechts D. Accelerated lung function decline in smokers: spotlight on vitamin D deficiency. Am J Respir Crit Care Med. 2012 Oct 1;186(7):579-81 (Comment on Vitamin D deficiency, smoking, and lung function in the Normative Aging Study. [Am J Respir Crit Care Med. 2012])
  86. Wedzicha JA, Seemungal TAR. Inhaled corticosteroids in COPD: a light at the end of the tunnel? Thorax 2005;60:977-978
  87. Wedzicha JA. Collaboration in inhaled steroids in COPD. Thorax 2005;60:977
  88. West R and Zhou X. Is nicotine replacement therapy for smoking cessation effective in the ‘‘real world’’? Findings from a prospective multinational cohort study. Thorax 2007;62:998–1002
  89. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respiratory Research 2011, 12:40 doi:10.1186/1465-9921-12-40
  90. Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD002878. DOI: 10.1002/14651858:CD002878
  91. Wilke S, Jones PW, Müllerova H, Vestbo J, Tal-Singer R, Franssen FM, Agusti A, Bakke P, Calverley PM, Coxson HO, Crim C, Edwards LD, Lomas DA, MacNee W, Rennard SI, Yates JC, Wouters EF, Spruit MA. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015 May;70(5):420-5.
  92. Wilson DH, Tucker G, Frith P, Appleton, S, Ruffin RE, Adams RJ. Trends in hospital admissions and mortality from asthma and chronic obstructive pulmonary disease in Australia 1993-2003. MJA 2007;186:408-411
  93. Williamson PA, Short PM, Clearie KL, Vaidyanathan S, Fardon TC, Howaniec LJ, Lipworth BJ. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD. Chest. 2010 Sep;138(3):595-604.
  94. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007 Nov 6;147(9):639-53
  95. Wong R, Sibley KM, Hudani M, Roeland S, Visconti M, Balsano J, Hill K, Brooks D. Characteristics of people with chronic lung disease who rest during the six-minute walk test. Arch Phys Med Rehabil. 2010 Nov;91(11):1765-9
  96. Wood AM, Harrison RM, Semple S, Ayres JG, Stockley RA. Outdoor air pollution is associated with rapid decline of lung function in alpha-1-antitrypsin deficiency. Occup Environ Med. 2010 Aug;67(8):556-61.
  97. Wood-Baker R, Walters J, Walters EH. Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir Med. 2007 Mar;101(3):371-7. Epub 2006 Sep 7
  98. Woods JA, Usery JB, Self TH, Finch CK. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations. South Med J. 2011 Nov;104(11):742-5
  99. Worth H, Schacher C, Dethlefsen U. Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial. Respiratory Research 2009, 10:69 doi:10.1186/1465-9921-10-69
  100. Xuan W, Correll P, Ampon R, Williamson M, Marks G. Time trends in hospitalisations and deaths due to COPD and asthma among persons aged 55 and over, 1997-2003. Australian Centre for Asthma Monitoring & Woolcock Institute of Medical Research (Poster)
  101. Yamaguti WP, Claudino RC, Neto AP, Chammas MC, Gomes AC, Salge JM, Moriya HT, Cukier A, Carvalho CR. Diaphragmatic Breathing Training Program Improves Abdominal Motion During Natural Breathing in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.  Arch Phys Med Rehabil 2012: 93(4): 571-7
  102. Yu AP, Guérin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med. 2011 Dec;105(12):1861-71
  103. Zainuldin R, Mackey MG, Alison JA. Optimal intensity and type of leg exercise training for people with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008008. DOI: 10.1002/14651858.CD008008.pub2
  104. Zaman M, Mahmood S, Altayeh A. Low inspiratory capacity to total lung capacity ratio is a risk factor for chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2010 May;339(5):411-4
  105. Zanobetti A, Bind MA, Schwartz J. Particulate air pollution and survival in a COPD cohort. Environ Health. 2008 Oct 10;7:48
  106. Zhang X, Waterman LA, Ward J, Baird JC, Mahler DA. Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest. 2010 Jun;137(6):1354-61
  107. Zheng J, Yang J, Zhou X, Zhao L, Hui F, Wang H, Bai C, Chen P, Li H, Kang J, Brose M, Richard F, Goehring U-M, Zhong N. Roflumilast for the Treatment of COPD in an Asian Population. Chest 2014; 145(1):44–52
  108. Zhou Y, Hu G, Wang D, Wang S, Wang Y, Liu Z, Hu J, Shi Z, Peng G, Liu S, Lu J, Zheng J, Wang J, Zhong N, Ran P. Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomized controlled trial. BMJ. 2010 Dec 1;341:c6387. doi: 10.1136/bmj.c6387
  109. Zoeckler N, Kenn K, Kuehl K, Stenzel N, Rief W. Illness perceptions predict exercise capacity and psychological well-being after pulmonary rehabilitation in COPD patients. J Psychosom Res. 2014;76(2):146-51
  110. Zwar N et al. A cluster randomised controlled trial of nurse and GP partnership for care of Chronic Obstructive Pulmonary Disease. BMC Pulmonary Medicine 2008, 8:8